Across 48 weeks of treatment, participants showed continued weight loss without any measurable decrease in the medications biological activity
Int J Clin Pract 74(10):e13586
The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide
According to the SmPC, these include: Nausea very common (may affect more than 1 in 10 people) Vomiting common (may affect up to 1 in 10 people) Abdominal pain and discomfort Diarrhoea or constipation Dyspepsia and reflux These symptoms can be particularly troublesome at night, especially if the evening meal is consumed close to bedtime
Supporting Your Master Antioxidant Levels Naturally While supplements are a powerful tool, they work best when supported by a healthy lifestyle
Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial